人 PLCB1 抗体对
01AB03475
1-Phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 (PLCB1) is an enzyme that catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), key secondary messengers in various signaling pathways. This enzyme plays a pivotal role in intracellular signal transduction, particularly in response to G-protein-coupled receptor activation, leading to increased intracellular calcium levels and subsequent cellular responses. Dysregulation of PLCB1 has been implicated in several diseases, particularly hepatocellular carcinoma (HCC), where its overexpression is associated with tumor progression and poor prognosis. Studies have shown that elevated PLCB1 expression correlates with advanced tumor stages and promotes cell proliferation while inhibiting apoptosis in HCC cells. Additionally, PLCB1 is involved in other conditions such as schizophrenia and myotonic dystrophy.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- PLCB1
- 基因别名
- KIAA0581
- 蛋白别名
- phospholipase C beta 1; PLCB1
- UniProt
- Q9NQ66
- 物种
- Human
产品详情
- 靶点名称
- PLCB1
- 蛋白名称
- phospholipase C beta 1
- 蛋白别名
- 1-phosphatidylinositol 4; 5-bisphosphate phosphodiesterase beta-1; PLC-154; Phosphoinositide phospholipase C-beta-1; Phospholipase C-I; PLC-I; Phospholipase C-beta-1; PLC-beta-1
- 靶点基因名
- PLCB1
- 基因别名
- KIAA0581
- UniProt
- Q9NQ66
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
1-Phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 (PLCB1) is an enzyme that catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), key secondary messengers in various signaling pathways. This enzyme plays a pivotal role in intracellular signal transduction, particularly in response to G-protein-coupled receptor activation, leading to increased intracellular calcium levels and subsequent cellular responses. Dysregulation of PLCB1 has been implicated in several diseases, particularly hepatocellular carcinoma (HCC), where its overexpression is associated with tumor progression and poor prognosis. Studies have shown that elevated PLCB1 expression correlates with advanced tumor stages and promotes cell proliferation while inhibiting apoptosis in HCC cells. Additionally, PLCB1 is involved in other conditions such as schizophrenia and myotonic dystrophy.